ADRX — ADARx Pharmaceuticals, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1802369 ·
Last close
$13.82
Market Cap
$1.53B
52W High
$23.21
52W Low
$12.50
ADV30
446,716
Next earnings
—
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation. It also offers extrahepatic-targeted programs, such as ADX-077, an adipose-targeted obesity program designed to reduce body weight and fat while preserving lean mass; and ADX-199, a neuron-targeted program designed to selectively silence and degrade amyloid-ß precursor protein (APP) mRNA in neurons, which is genetically linked to Alzheimer's disease. The company was incorporated in 2019 and is based in San Diego, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 2,217,000 — -32,177,000 -28,117,000 929,064,000 570,610,000 354,662,000
Jun 2026 746,000 — -29,891,000 -25,759,000 456,332,000 58,484,000 707,384,000
Mar 2026 2,140,000 — -27,056,000 -22,667,000 482,558,000 63,858,000 708,290,000
Dec 2025 — — — — 507,655,000 66,517,000 709,910,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$250,868,000
Investing CF
$-207,501,000
Financing CF
$91,000
CapEx
$-1,933,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.43
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-269,125,000
Inventory
—
Receivables
—
ST Investments
$368,768,000
EBIT TTM
$-95,957,000
Pretax Income TTM
$-82,070,000
Interest Exp TTM
—
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$6,127,000
EBITDA
$-105,124,000
Free Cash Flow
—
Enterprise Value
$1,450,645,888
Total Cash
$427,252,000
Total Debt
$6,898,000
Shares Out
110,738,825
Trailing EPS
$-1.16
Book Value
$-22.16
ROE
—
ROA
—
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 2y)

Revenues vs Net Income (last 2y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 3,449,000 -88,365,000 -73,088,000 507,655,000 709,910,000 -202,255,000 262,288,000
Dec 2024 0 -58,233,000 -46,360,000 233,454,000 370,599,000 -137,145,000 -48,563,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.51

Peers — same industry

TickerNameMarket CapLastDaily %
PGEN PRECIGEN, INC. $1.54B $4.29 —
NRIX Nurix Therapeutics, Inc. $1.56B $14.24 —
KRSA Korsana Biosciences, Inc. $1.48B $32.50 —
SRPT Sarepta Therapeutics, Inc. $1.58B $14.77 —
KLRA Kailera Therapeutics, Inc. $1.58B $12.20 —

News headlines (Yahoo Finance, 1h cache)

ADARx Reports Third Quarter 2026 Financial Results and Provides Business Updates
2026-11-12 21:05 · Yahoo
ADARx Pharmaceuticals to Present at the UBS Global Biopharma Conference
2026-11-09 13:00 · Yahoo
ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offering
2026-10-01 20:15 · Yahoo
ADARx Pharmaceuticals (ADRX) Moved Higher, But What Is Drawing Attention?
2026-09-28 03:10 · Yahoo
ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering
2026-09-24 23:33 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.